Obesity drugs put these stocks on a crash diet—now they're rebounding

Medical-device investors bet new obesity drugs won't cause as much pain as previously thought.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...